Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A phase II, multicenter, open label study of treatment escalation to ACVD (Adriamycin, Cyclophosphamide, Vinblastine and Dacarbazine) and Brentuximab-Vedotin in advanced-stage Hodgkin Lymphoma patients with a positive interim PET scan after 2 ABVD cycles (OPTIMIST study) | KAIMRC | Ongoing | • DOXORUBICIN HYDROCHLORIDE• CYCLOPHOSPHAMIDE• VINBLASTINE SULPHATE • DACARBAZINE• BRENTUXIMAB VEDOTIN | 2 | RC16/150 | King Abdulaziz Medical City NG (Riyadh) |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2) | Albireo | Ongoing | A4250 | 3 | A4250-008 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C<2%) (BeneGene-2) | Pfizer | Ongoing | PF-06838435 | 3 | C0371002 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| "ALL SCTped 2012 FORUMAllogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia" | KAIMRC | Completed | • BUSULFAN• FLUDARABINE PHOSPHATE• ETOPOSIDE | 3 | CT17/016/R | King Abdulaziz Medical City NG (Riyadh) |
| Re-challenge therapy with chemotherapy and panitumumab in metastatic colorectal cancer patients treated with an anti-EGFR therapy in 1st line treatment: a phase II multicentre study. | King Abdullah Medical City, Holy Capital | Ongoing | • PANITUMUMAB• OXALIPLATIN• irinotecan• FLOUROURACIL | 2 | 19-504 | King Abdullah Medical City (Makkah) |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the Tocilizumab followed by cisplatin/docetaxel in patients with triple negative locally advanced breast cancer | King Faisal Specialist Hospital and Research Centre | Ongoing | • TOCILIZUMAB (ACTEMRA)• DOCETAXEL (TAXOTERE)• CISPLATIN | 2a | 2181156 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension | Biogen | Ongoing | Interferon beta-1a | 3 | 105MS306 | King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh) |
| "A multicenter, multinational, prospective, interventional,single-arm, Phase IV study evaluating the clinicalefficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin" | SANOFI | Ongoing | TOUJEO | 4 | LPS15396 | Sultan bin Abdulaziz Humanitarian city (Riyadh) |
| "A multi-centre prospective non-interventional studyinvestigating the clinical effectiveness of Ryzodeg® (InsulinDegludec/Insulin Aspart) in patients with type 2 diabetesmellitus in a real-world setting" | Novo Nordisk | Ongoing | Ryzodeg Flex Touch | 4 | NN54014525 | King Abdulaziz University Hospital (Jeddah), Ghassan Najeeb Pharaon hospital (Jeddah), Saudi German Hospital (Jeddah), Umm Al-Qura University (Makkah), Dallah Hospital (Riyadh), Riyadh Care Hospital (Riyadh), Specialized Medical Center (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| A prospective Randomized study of General Anesthesia versus Anesthetist Administered sedation for ERCP | King Abdullah Medical City (Makkah) | Ongoing | FENTANYL/ CISATRACURIUM/ SEVOFLURANE | 4 | 18-492 | King Abdullah Medical City (Makkah) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.